In June 2020, the US company announced a co-development agreement with Farmacore Biotechnology for Versamune-CoV-2FC, a vaccine aimed at preventing COVID-19 infection.

Under the collaboration, PDS Biotech and Farmacore will accelerate development of Versamune-CoV-2FC into Phase I clinical testing in Brazil, with initial financial support provided by the Brazilian Ministry of Science, Technology, Innovation and Communication.